WuXi Biologics (Cayman) Inc. (WXIBF)
The price, the headline numbers and the latest news, in one place.
WuXi Biologics (Cayman) Inc. (WXIBF) Stock Price, Analysis & Data
No data available
| Bid | 6.05 |
| Market Cap | 25.6B |
| Revenue (ttm) | 23.6B |
| Net Income (ttm) | 5.01B |
| 0.62 | |
| 0.17 | |
| 36.62 | |
| n/a | |
| P/B (ttm) | 3.68 |
| P/S (ttm) | 1.08 |
| Earnings Date | Mar 30, 2027 |
| Ask | 6.65 |
| Volume | 4,000 |
| Avg. Volume (20D) | 749 |
| Open | 6.45 |
| Previous Close | 6.22 |
| Day's Range | 6.45 - 6.45 |
| 52-Week Range | 3.90 - 6.45 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About WXIBF
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, Australia, and Brazil. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly...
Financial Performance
In 2025, WuXi Biologics (Cayman)'s revenue was 21.79B, an increase of 16.68% compared to the previous year's 18.68B. Earnings were 4.91B, an increase of 46.25%.
Financial StatementsEarnings Surprise
- Revenue of n/a misses estimates by $0, with NaN% YoY growth.
- EPS of misses estimates by , with NaN% YoY growth.
Analysts project revenue of ... Upgrade
6 months ago · Simply Wall St.
WuXi Biologics Awards Win And Earendil Deal Viewed Against ValuationWuXi Biologics (Cayman) reported a record haul of trophies at the 2026 Asia Pacific Biopharma Excellence Awards, covering biologics development, manufacturing, and digital capabilities. The company al...
6 months ago · Simply Wall St.
Vertex Autoimmune Deal With WuXi Adds New Angle To VRTX Valuation StoryVertex Pharmaceuticals (NasdaqGS:VRTX) has signed a license and research agreement with WuXi Biologics for a trispecific T cell engager targeting B cell mediated autoimmune diseases. The deal gives Ve...